Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -4.17% is 84% above its 5-year average of -26.87%, near the high end of its 5-year range (-57.27%–0.14%).
50.45% above its 12-month average of -8.41%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -7.55%.
RETURN ON ASSETS (ROA)
-4.17%
RETURN ON ASSETS (ROA) AVG TTM
-8.41%
RETURN ON ASSETS (ROA) AVG 3Y
-15.90%
RETURN ON ASSETS (ROA) AVG 5Y
-26.87%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+50.45%
CURRENT VS 3Y AVG
+73.78%
CURRENT VS 5Y AVG
+84.48%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+87.08%
vs the sector median at left
Xeris Biopharma Holdings, Inc.
Market Cap
$1.74B
Return on Assets (ROA)
-4.17%
TTM Avg
-8.41%
3Y Avg
-15.90%
5Y Avg
-26.87%
Market Cap
$1.74B
Return on Assets (ROA)
-45.02%
TTM Avg
-50.76%
3Y Avg
-46.27%
5Y Avg
-37.50%
Market Cap
$1.74B
Return on Assets (ROA)
3.18%
TTM Avg
-8.22%
3Y Avg
-16.26%
5Y Avg
-17.13%
Market Cap
$1.74B
Return on Assets (ROA)
-18.68%
TTM Avg
-15.27%
3Y Avg
-14.09%
5Y Avg
-9.93%
Market Cap
$1.73B
Return on Assets (ROA)
-46.66%
TTM Avg
-46.30%
3Y Avg
-40.19%
5Y Avg
-33.55%
Market Cap
$1.75B
Return on Assets (ROA)
-1.10%
TTM Avg
-1.54%
3Y Avg
-1.02%
5Y Avg
-1.23%
Market Cap
$1.71B
Return on Assets (ROA)
-34.34%
TTM Avg
-27.20%
3Y Avg
-35.30%
5Y Avg
-29.09%
Market Cap
$1.77B
Return on Assets (ROA)
-61.53%
TTM Avg
-47.53%
3Y Avg
-47.53%
5Y Avg
-47.53%
Market Cap
$1.71B
Return on Assets (ROA)
-10.49%
TTM Avg
-13.41%
3Y Avg
-10.26%
5Y Avg
-6.23%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | $1.74B | -4.17% | -8.41% | -15.90% | -26.87% |
| Absci Corporation (ABSI)vs › | $1.74B | -45.02% | -50.76% | -46.27% | -37.50% |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.74B | 3.18% | -8.22% | -16.26% | -17.13% |
| Novocure Ltd (NVCR)vs › | $1.74B | -18.68% | -15.27% | -14.09% | -9.93% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.73B | -46.66% | -46.30% | -40.19% | -33.55% |
| Surgery Partners, Inc. (SGRY)vs › | $1.75B | -1.10% | -1.54% | -1.02% | -1.23% |
| Personalis, Inc. (PSNL)vs › | $1.71B | -34.34% | -27.20% | -35.30% | -29.09% |
| Generate Biomedicines, Inc. (GENB)vs › | $1.77B | -61.53% | -47.53% | -47.53% | -47.53% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | -10.49% | -13.41% | -10.26% | -6.23% |
| Zenas BioPharma, Inc. (ZBIO)vs › | $1.70B | -69.03% | -70.44% | -88.82% | -88.82% |
ROA
-4.2%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 0.14% |
| 2024-12-31 | -16.97% |
| 2023-12-31 | -19.30% |
| 2022-12-31 | -27.48% |
| 2021-12-31 | -40.32% |
| 2020-12-31 | -57.27% |
| 2019-12-31 | -115.22% |
| 2018-12-31 | -50.05% |
| 2017-12-31 | -59.01% |
| 2016-12-31 | -39.39% |
